Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-15


Brief Information

Target Synonym:IL-15,Interleukin-15,IL15,Interleukin 15,MGC9721
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IL5-H5257-Cell-based assay

Human IL-15 Protein, Fc Tag (Cat. No. IL5-H5257) stimulates proliferation of CTLL-2 cells. The typically EC50 for this effect is 2.483 ng/mL (QC tested).

IL5-H5215-Cell-based assay

Human IL-15, premium grade (Cat. No. IL5-H5215) stimulates proliferation of CTLL-2 cells. The specific activity of Human IL-15, premium grade is > 0.80×10^7 IU/mg, which is calibrated against human IL-15 WHO International Standard (NIBSC code: 95/554) (QC tested).

 IL-15 SPR

Biotinylated Human IL-15 R alpha, Fc,Avitag (Cat. No. ILA-H82F4) immobilized on CM5 Chip can bind Human IL-15 Protein, Fc Tag (Cat. No. IL5-H5257) with an affinity constant of 27.7 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

 IL-15 SPR

Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human IL-15, premium grade (Cat. No. IL5-H4117) with an affinity constant of 9.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name



Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BNZ-1 BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 Phase 2 Clinical Bioniz Therapeutics Inc Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details
Ordesekimab HuMab-IL15; AMG-714; PRV-015 Phase 2 Clinical Provention Bio Inc, Genmab A/S, Amgen Inc Arthritis, Rheumatoid; Celiac Disease; Psoriasis; Lymphoma, T-Cell; Vitiligo Details
HCW-9218 HCW-9218 Phase 2 Clinical HCW Biologics Inc Solid tumours; Pancreatic Neoplasms; Pulmonary Fibrosis Details
NY-ESO-1 TCR/IL-15 NK Phase 2 Clinical The University Of Texas MD Anderson Cancer Center, Syena, Replay Holdings LLC Sarcoma, Synovial; Multiple Myeloma; Liposarcoma, Myxoid Details
IL15-transpresenting WT1-targeted Dendritic Cell Vaccine(Antwerp University Hospital) Phase 2 Clinical Antwerp University Hospital Liver Neoplasms; Ovarian Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms Details
CAR-5/IL-15-transduced CB-NK cell therapy Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Hematologic Neoplasms Details
Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) VG-161 Phase 2 Clinical Cnbg-Virogin Biotech (Shanghai) Ltd Solid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Cholangiocarcinoma; Carcinoma, Hepatocellular Details
XmAb24306 XmAb-24306; RG-6323; RO-7310729; XmAb-306 Phase 1 Clinical Genentech Inc, Xencor Inc Solid tumours; Neoplasms; Multiple Myeloma Details
SIM-0237 SIM-0237 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Urinary Bladder Neoplasms Details
CYTO-102 CYTO-NK-102; CYTO-102; COH06 Phase 1 Clinical CytoImmune Therapeutics Inc Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
VG-201 VG-201 Phase 1 Clinical ViroGin Biotech Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
VG-203 VG-203; VG2062; VG-2062 Phase 1 Clinical ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Breast Neoplasms Details
ACTM-838 ACTM838 Phase 1 Clinical Actym Therapeutics Inc Solid tumours Details
CALY-002 CALY-002 Phase 1 Clinical Idd Biotech Eosinophilic Esophagitis; Celiac Disease Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message